Innovations + Investments in Healthcare Summit 2015

Breaking World Pharma News

Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark

Novo NordiskNovo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.

Read more...

Adverse effects of common prostate enlargement and hair growth drugs

Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss (known as alopecia) are also at risk for adverse events elicited by these drugs.

Read more...

Scientists discover electrical control of cancer cell growth

The molecular switches regulating human cell growth do a great job of replacing cells that die during the course of a lifetime. But when they misfire, life-threatening cancers can occur. Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.

Read more...

AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

AstraZenecaAstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine's investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736).

Read more...

Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications

NovartisNovartis announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications.

Read more...

Patent expirations for blockbuster antipsychotic meds could save billions

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue.

Read more...

FDA approves first treatment for sexual desire disorder

The U.S. Food and Drug AdministrationThe U.S. Food and Drug Administration today approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi's approval, there were no FDA-approved treatments for sexual desire disorders in men or women.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]